Stay updated with breaking news from Mylan pharm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Federal Circuit provided its latest guidance with respect to prosecution disclaimer in K-fee System GMBH v. Nespresso USA, Inc., 2023 WL 8882383, — F.4th — (Fed. Cir. Dec. 26, 2023). ....
The Federal Circuit provided its latest guidance with respect to prosecution disclaimer in K-fee System GMBH v. Nespresso USA, Inc., 2023 WL 8882383, F.4th (Fed. Cir. Dec. 26,. ....
In Sanofi-Aventis Deutschland GmbH v. Mylan Pharm. Inc., Case No. 2021-1981, the Federal Circuit reversed an obviousness determination by the PTAB. At issue was Sanofi’s reissued U.S.. ....
The Supreme Court recently agreed to review the enablement standard for genus claims,[1] the first time the Court has considered 35 U.S.C. § 112 since evaluating the standard. ....
In Mylan Pharm. Inc. v. Merck Sharp & Dohme Corp., the Federal Circuit considered whether prior disclosure of a genus of compounds and their pharmaceutically acceptable salts was. ....